Toll-like receptor (TLR) 9 variant is associated with mother-to-child transmission (MTCT) of HIV-1 and TLR9 and TLR8 variants are associated with peak viral load in HIV-1-positive infants

被引：0
|
作者：
Beima-Sofie, K. [1 ]
Bigham, A. [2 ]
Lingappa, J. R. [1 ]
Wamalwa, D. [3 ]
Mackelprang, R. D. [1 ]
Maleche-Obimbo, E. [3 ]
Richardson, B. [1 ]
John-Stewart, G. [1 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
[3] Univ Nairobi, Nairobi, Kenya
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2012年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：20 / 21
页数：2
相关论文
共 50 条
  • [41] Toll-like receptor (TLR)7 and TLR9 agonists enhance interferon (IFN) beta-1a's immunoregulatory effects on B cells in patients with relapsing-remitting multiple sclerosis (RRMS)
    Tao, Yazhong
    Zhang, Xin
    Markovic-Plese, Silva
    JOURNAL OF NEUROIMMUNOLOGY, 2016, 298 : 181 - 188
  • [42] INTRATUMORAL INJECTION OF CMP-001, A TOLL-LIKE RECEPTOR 9 (TLR9) AGONIST, IN COMBINATION WITH PEMBROLIZUMAB REVERSED PROGRAMMED DEATH RECEPTOR 1 (PD-1) BLOCKADE RESISTANCE IN ADVANCED MELANOMA
    Milhem, Mohammed
    Zakharia, Yousef
    Davar, Diwakar
    Buchbinder, Elizabeth
    Medina, Theresa
    Daud, Adil
    Ribas, Antoni
    Niu, Jiaxin
    Gibney, Geoffrey
    Margolin, Kim
    Olszanski, Anthony
    Mehmi, Inderjit
    Sato, Takami
    Shaheen, Montaser
    Morris, Aaron
    Mauro, David
    Campbell, Katie
    Kelley, Heather
    Bao, Riyue
    Weiner, George
    Luke, Jason
    Krieg, Arthur
    Wooldridge, James
    Kirkwood, John
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A186 - A187
  • [43] DURABLE RESPONSES IN ANTI-PD-1 REFRACTORY MELANOMA FOLLOWING INTRATUMORAL INJECTION OF A TOLL-LIKE RECEPTOR 9 (TLR9) AGONIST, CMP-001, IN COMBINATION WITH PEMBROLIZUMAB
    Milhem, Mohammed
    Zakharia, Yousef
    Davar, Diwakar
    Buchbinder, Elizabeth
    Medina, Theresa
    Daud, Adil
    Ribas, Antoni
    Niu, Jiaxin
    Gibney, Geoffrey
    Margolin, Kim
    Olszanski, Anthony
    Mehmi, Interjit
    Sato, Takami
    Shaheen, Montaser
    Morris, Aaron
    Mauro, David
    Campbell, Katie
    Bao, Riyue
    Weiner, George
    Luke, Jason
    Krieg, Arthur
    Kirkwood, John
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A2 - A3
  • [44] A novel role for Toll-Like Receptor-3 in sensing HIV-1 infection: potential implications in viral replication, immune activation and HIV-1 associated neuropathogenesis
    Swaminathan, Gokul
    Perales-Linares, Renzo
    Navas-Martin, Sonia
    Martin-Garcia, Julio
    JOURNAL OF NEUROVIROLOGY, 2013, 19 : S79 - S80
  • [45] TLR9 (Toll-Like Receptor 9) Agonist Suppresses Angiogenesis by Differentially Regulating VEGFA (Vascular Endothelial Growth Factor A) and sFLT1 (Soluble Vascular Endothelial Growth Factor Receptor 1) in Preeclampsia
    He, Biwei
    Yang, Xingyu
    Li, Yamei
    Huang, Ding
    Xu, Xin
    Yang, Wenjun
    Dai, Yan
    Zhang, Huijuan
    Chen, Zhengjun
    Cheng, Weiwei
    HYPERTENSION, 2018, 71 (04) : 671 - 680
  • [46] Induction of HIV-1 Gene Expression in Human Monocytic Cells by the Failed Microbicide Carrageenan Occurs Through Activation of Toll-like Receptor 4 (TLR4)
    Keogan, Shawn
    Pirrone, Vanessa
    Passic, Shendra
    Wigdahl, Brian
    Krebs, Fred
    ANTIVIRAL RESEARCH, 2009, 82 (02) : A64 - A64
  • [47] Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma
    Milhem, Mohammed
    Gonzales, Rene
    Medina, Theresa
    Kirkwood, John M.
    Buchbinder, Elizabeth
    Mehmi, Inderjit
    Niu, Jiaxin
    Shaheen, Montaser
    Weight, Ryan
    Margolin, Kim
    Luke, Jason
    Morris, Aaron
    Mauro, David
    Krieg, Arthur M.
    Ribas, Antoni
    CANCER RESEARCH, 2018, 78 (13)
  • [48] Brief Report: Toll-like Receptor 9-1635A/G Polymorphism Is Associated With HIV-1 Rebound After Four Weeks of Interruption of Antiretroviral Therapy
    Vallejo, Alejandro
    Molina-Pinelo, Sonia
    de Felipe, Beatriz
    Abad-Fernandez, Maria
    Gonzalez-Escribano, Maria Francisca
    Leal, Manuel
    Soriano-Sarabia, Natalia
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 85 (02) : 252 - 256
  • [49] Phase 1 study of the toll-like receptor 9 (TLR9) agonist, IMO-2055, combined with erlotinib (E) and bevacizumab (B) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC)
    Smith, D. A.
    Conkling, P.
    Richards, D.
    Alemany, C.
    Boyd, T.
    Garbo, L.
    Wu, H.
    Wages, D.
    Bexon, A.
    Murphy, J.
    EJC SUPPLEMENTS, 2009, 7 (02): : 549 - 550
  • [50] INTRAVENOUS CMP-001, A CPG-A TOLL-LIKE RECEPTOR 9 (TLR9) AGONIST DELIVERED VIA A VIRUS-LIKE PARTICLE, CAUSES TUMOR REGRESSION IN SYNGENEIC HEPA1-6 MOUSE MODELS OF HEPATOCELLULAR CARCINOMA
    Morris, Aaron
    Walters, Evan
    Akache, Bassel
    McCluskie, Michael
    Krieg, Arthur
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A360 - A361
12345